# EDGAR Filing Document

**Accession Number:** 0000883975
**File Stem:** 0001641172-25-024927
**Filing Date:** 2025-8
**Character Count:** 12778
**Document Hash:** 07677a1c504b5f4cfb38e9141e9a2b9c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-024927.hdr.sgml**: 20250820

**ACCESSION NUMBER**: 0001641172-25-024927

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250820

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250820

**DATE AS OF CHANGE**: 20250820

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Microbot Medical Inc.
- **CENTRAL INDEX KEY:** 0000883975
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943078125
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19871
- **FILM NUMBER:** 251233997

**BUSINESS ADDRESS:**
- **STREET 1:** 25 RECREATION PARK DR SUITE 108
- **CITY:** HINGHAM
- **STATE:** MA
- **ZIP:** 02043
- **BUSINESS PHONE:** 908-938-5561

**MAIL ADDRESS:**
- **STREET 1:** 25 RECREATION PARK DR SUITE 108
- **CITY:** HINGHAM
- **STATE:** MA
- **ZIP:** 02043

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STEMCELLS INC
- **DATE OF NAME CHANGE:** 20000524

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTOTHERAPEUTICS INC/DE
- **DATE OF NAME CHANGE:** 19930328

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 20, 2025**

**MICROBOT MEDICAL INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-19871** | **94-3078125** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

**175 Derby St., Bld. 27**

**Hingham, MA 02043**

**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (781) 875-3605**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.01 par value | MBOT | NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On August 20, 2025, Microbot Medical Inc. (the "Company") issued a press release announcing that the United States Patent and Trademark Office ("USPTO") has granted the Company a patent, covering a modular robotic surgical system which includes a base and a plurality of tool-receiver units arranged as separate units and independently and interchangeably attachable to the base (the "Patent").

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

**Item 8.01 Other Events.**

The USPTO granted the Patent to the Company, which will potentially enable its LIBERTY device to be adapted in the future for a wider range of endovascular procedures, which would increase substantially the Total Addressable Market (TAM) the Company is aiming to penetrate. The Patent expands the Company's intellectual property protection in the United States for its LIBERTY<sup>®</sup> system portfolio, which now includes 12 patents granted globally and 57 patent applications pending.

***Forward Looking Statements***

 ****

This Item 8.01 of this Current Report on Form 8-K may contain "forward-looking statements." Such statements which are not purely historical (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "intends," "would," "could" and "estimates") are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company's reports and statements filed from time-to-time with the Securities and Exchange Commission.

**Item 9.01. Financial Statements and Exhibits.**

***(d) Exhibits***

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| 99.1 | [Press Release](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| **MICROBOT MEDICAL INC.** | **MICROBOT MEDICAL INC.** |
| By: | */s/ Harel Gadot* |
| Name: | Harel Gadot |
| Title: | Chief Executive Officer, President and Chairman |

---

Date: August 20, 2025

## Exhibit 99.1

**Exhibit 99.1**

**Microbot Medical<sup>®</sup> Granted U.S. Patent that Significantly Expands Potential Market Applications**

*With the Newly Granted IP, the Company's IP Portfolio for the LIBERTY*<sup>®</sup> *System now includes 12 patents granted globally and 57 patent applications pending.*

 

*The Company Continues to Scale Commercial Readiness Plans for the LIBERTY*<sup>®</sup> *System as it Awaits FDA Decision.*

**HINGHAM, Mass., August 20, 2025** — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY<sup>®</sup> Endovascular Robotic System, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent, covering a modular robotic surgical system which includes a base and a plurality of tool-receiver units arranged as separate units and independently and interchangeably attachable to the base. The Company considers the issuance of this patent to be significant, as it will potentially enable LIBERTY<sup>®</sup> to be adapted in the future for a wider range of endovascular procedures, which would increase substantially the Total Addressable Market (TAM) the Company is aiming to penetrate. This patent expands the Company's intellectual property protection in the United States for its LIBERTY<sup>®</sup> system portfolio, which now includes 12 patents granted globally and 57 patent applications pending.

The patent supports innovation and customization for different clinical needs, that would allow the Company to address other indications and significantly increase its potential customer base. The Company now has the flexibility and protection to continue building additional capabilities and features to enhance the LIBERTY<sup>®</sup> System, with the potential to eventually expand well beyond the estimated 2.5 million peripheral endovascular procedures performed in the U.S., annually.

"We believe LIBERTY<sup>®</sup> is one of the most advanced and distinctive robotic systems in the world, being the first fully disposable robotic system along with other unique features such as its modular capabilities. This patent recognizes yet another layer of our differentiation and could expand our reach to over 6 million annual endovascular procedures in the U.S. alone," commented Harel Gadot, Chairman, CEO & President. "Our near-term focus remains on the peripheral market and ensuring our commercial readiness plans in the U.S. are progressing as we await the FDA's decision."

LIBERTY<sup>®</sup> is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S.

**About Microbot Medical**

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.

Further information about Microbot Medical<sup>®</sup> is available at <u>http://www.microbotmedical.com</u>.

**Safe Harbor**

Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as "contemplates," "continues," "could," "forecasts," "intends," "may," "might," "possible," "potential," "predicts," "projects," "should," "would," "will," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical<sup>®</sup> can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at <u>www.sec.gov</u>. Microbot Medical<sup>®</sup> disclaims any intent or obligation to update these forward-looking statements, except as required by law.

**Investor Contact:**

<u>IR@microbotmedical.com</u>